Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof

Abstract

The present invention describes methods for producing binding sites on polypeptides, and particularly for producing binding sites within the CDR regions of immunoglobulin heavy or light chains that are displayed on the surface of filamentous phage particles. The invention also describes oligonucleotides useful for preparing the binding sites, and human monoclonal antibodies produced by the present methods.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of application Ser. No. 08 / 495,606, filed Aug. 21, 1995, pending, which is a U.S. National Phase application based on International application Ser. No. PCT / US94 / 01258 filed Feb. 2, 1994, which is a continuation-in-part of U.S. patent application Ser. No. 08 / 084,542, filed Jun. 28, 1993, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 08 / 012,566, filed Feb. 2, 1993, now abandoned.TECHNICAL FIELD [0002] The present invention relates generally to the field of protein biochemistry and immunology, and relates specifically to methods for producing polypeptide binding sites specific for preselected targets. BACKGROUND [0003] Protein interactions with other molecules is basic to biochemistry. Protein interactions include receptor-ligand interactions, antibody-antigen interactions, cell-cell contact and pathogen interactions with target tissues. Protein interactions can involve...

AI Technical Summary

Benefits of technology

The patent describes methods for creating binding sites in a polypeptide that can interact with various target molecules. These methods involve introducing a nucleotide sequence that codes for an amino acid residue sequence that defines the binding site. The nucleotide sequence is designed to bind to specific regions of the immunoglobulin gene. The methods can be applied to create binding sites for a variety of target molecules, such as CD4 receptors, vitronectin receptors, and platelet glycoprotein gpIIb / IIIa. The patent also describes monoclonal antibodies and polypeptides that can be used for therapeutic purposes. The invention provides a way to create new binding specificities that can be used for research and development of new drugs.

Problems solved by technology

Typically, the mutagenesis is site-directed, and therefore laborious depending on the systematic choice of mutation to induce in the protein.

Images